Rafferty Asset Management
DNA icon

Rafferty Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Rafferty Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,091
Closed -$468K – 1180
2024
Q1 		$468K Sell
10,091
-1,183
-10% -$61.2K ﹤0.01% 991
2023
Q4 		$762K Buy
11,274
+1,482
+15% +$90.7K ﹤0.01% 866
2023
Q3 		$709K Sell
9,792
-120
-1% -$9.59K ﹤0.01% 864
2023
Q2 		$737K Buy
9,912
+223
+2% +$13.2K ﹤0.01% 893
2023
Q1 		$515K Sell
9,689
-88
-0.9% -$5.58K ﹤0.01% 930
2022
Q4 		$661K Buy
9,777
+938
+11% +$86.3K 0.01% 848
2022
Q3 		$1.1M Buy
8,839
+8,298
+1,534% +$989K 0.01% 647
2022
Q2 		$52K Buy
+541
New +$66K ﹤0.01% 1100

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Rafferty Asset Management's DNA Position: Q2 2024 in Review

Rafferty Asset Management sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 10,091 shares — an estimated $468K sold.

Rafferty Asset Management first reported a position in DNA in Q2 2022 and held it in 8 quarters. The position peaked at $1.1M in Q3 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Rafferty Asset Management reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 10,091 Ginkgo Bioworks shares in Q2 2024, an estimated $468K.
  • Rafferty Asset Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 8 quarters.
  • Rafferty Asset Management's Ginkgo Bioworks position peaked at $1.1M in Q3 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Rafferty Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.